Skip to main content

Table 1 Main characteristics of the studies included in the meta-analysis

From: Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis

Authors year CSC markers Country duration Mean/median age (month) Sample size (n) Gender (M/F) TNM stage Cut-off value Follow-up (month) Outcome Hazard ratio (HR) NOS score#
Wang
2011 [18]
CD44, CD133 Singapore
2000–2004
64 116 76/36 I–IV CD44: 5 score (0–300)
CD133: 50 score (0–300)
110 OS E 8
Wakamatsu
2012 [19]
CD44, CD133, ALDH1 Japan
NR
65 190 NR I–IV  > 10% 83 OS CD44, CD133: R-Multi
ALDH1: R-Uni
6
Chen
2013 [20]
CD44, CD133 China
2000–2005
55 (23 to 84) 152 101/51 I–IV CD44: > 65%
CD133: > 50%
48.6 (1.0–76.7) OS, DFS OS: R-Multi
DFS: E
9
Cao
2014 [21]
CD44 China
2005–2007
60.5 (33–88) 203 140/63 NR  > 10% 66 (7–108) OS E 6
Cao
2014 [22]
CD44, CD24 China
2000–2010
64 (32 to 87) 290 221/69 I–IV  ≥ 30 (0–300) 41(3–135) OS R-Multi 9
Jian-Hui
2016 [23]
CD44, Gli-1, Shh China
2006
60 101 62/39 I–III  ≥ 4 score (0–12) 90 OS, DFS CD44, Shh: R-Uni
Gli: R-Multi
8
Zhang
2016 [24]
CD44, CD133, Sox-2, Oct-4, Gli-1 China
2005–2011
NR 101 NR I–IV  > 10% 80 OS E 6
Kodama
2017 [25]
CD44, CD44v6, CD44v9 Japan
2007–2009
70 (38–91) 123 83/40 I–IV  > 5% 68 (1–97) DSS R-Uni 7
Senel
2017 [26]
CD44, ALDH1 Turkey
2011–2015
NR 80 48/32 I–III  > 1 score (0–3) 60 DFS E 7
Sun
2017 [27]
CD44 China
2004–2012
60 200 135/65 I–IV  > 3 score (0–6) 110 OS E 8
Tongtawee
2017 [28]
CD44 Thailand
2011–2015
61.38 ± 12.39 162 117/45 I–IV  > 0 score (0–3) 60 OS R-Multi 8
Ryu
2018 [29]
CD44 Korea
1998–2009
60.7(27–84) 143 91/52 NR  > 2 score (0–3) 45 (0–155) OS, DFS R-Multi 7
Ibrahim
2019 [30]
CD44 Egypt
2012–2016
52.5(41–60) 40 25/15 I–III  > 10% 8–36 OS, DFS R-Uni 9
Xie
2015 [31]
CD44v6 China
2006–2008
60 208 154/54 I–IV  > 3 score 80 OS R-Multi 8
Xu
2017 [32]
CD44v6 China
2006–2013
60 103 69/34 I–IV NR 120 OS E 7
Yamaguchi
2002 [33]
CD44v6 Japan
1984–1993
NR 201 NR I–IV NR 144 OS E 6
Zheng
2017 [34]
CD44v6 China
2010–2015
65 (43–80) 49 39/10 NR NR 33 (1–73) DSS R 9
Hirata
2013 [35]
CD44v9 Japan
2008–2010
67.5 (46–90) 65 56/9 NR 3.58 ± 7.74% 32 (1–36) RFS R-Multi 7
Yamakawa
2017 [36]
CD44v9 Japan
2011–2012
70 103 79/24 I–IV  ≥ 4 score 61.0 RFS R-Multi 8
Go
2016 [37]
CD44v9 Korea
1999–2007
24–85 333 218/115 I–III  > 0 score (0–3) 120 OS E 8
Songun
2005 [38]
CD44v9 Netherlands
1989–1993
64.7 (31–84) 300 181 /119 I–IV  ≥ 5% 120 OS E 6
Ishigami
2010 [39]
CD133 Japan
2001–2003
65 (40 to 85) 97 69/28 I–IV containing at least one CD133 positive cell 60 OS E 8
Yu
2010 [40]
CD133 China
2004–2009
62.0 (29–83) 99 69/30 I–IV NR 26.76 ± 17.02 OS R-Multi 8
Zhao
2010 [41]
CD133 China
NR
58.1 (18–85) 336 274/62 I–IV  ≥ 5 score (0–12) 120 OS E 7
Lee
2012 [42]
CD133 Korea
2001–2005
61.5 (29–89) 100 71/29 II–III  ≥ 6 score (0–12) 46.9 (0–115) OS, DFS R-Multi 8
Hashimoto
2014 [43]
CD133 Japan
2004–2006
66 ± 11 189 133/56 I–IV  > 5% 60 OS E 7
Zhou
2015 [44]
CD133, LGR-5 China
2004–2006
59.6 (23–88) 261 172/89 I–IV  > 2 score (0–12) 43.9 (0–110) OS R-Multi 7
Lu
2017 [45]
CD133 China
2010–2011
58.1 ( 28–78) 236 159/77 I–III  ≥ 3 score (0–12) 48.6 (9–72) OS R-Multi 7
Attia
2019 [46]
CD133 Egypt
2012–2015
54.44 (24–81) 77 45/32 I–IV  > 3.5 score (0–6) NR RFS R 6
Liu
2019 [47]
CD133, ALDH1 China
2012–2017
53 (32–76) 91 69/22 III  ≥ 5 score (0–12) 27 (1–60) OS, DFS OS: E
DFS:R-multi
7
Matsuoka
2012 [48]
Sox-2, Oct-4, Nanog Japan
NR
NR 290 NR I–IV  ≥ 5 score (0–5) 120 OS R-Uni 6
Li
2015 [49]
SOX-2, Oct-4, Nanog China
2008–2009
55 (28–78) 69 41/18 I–III  ≥ 5 score (0–5) 35(6–60) OS, DFS E 8
Yang
2017 [50]
Sox-2, ALDH1 China
2010–2013
63 (29–82) 122 100/22 I–IV  > 5% 26 (1 to 75) OS Sox-2: R-Multi
ALDH1: R-Uni
8
Zhang
2010 [51]
Sox-2 China
2004
57.8 ( 29–79) 50 35/15 I–IV  > 10% 1–50 OS E 7
Camilo
2014 [52]
Sox-2 Portugal
1988–2010
66.5 (24–89) 201 124/77 I–IV  > 5% 250 OS E 8
Kong
2014 [53]
Oct-4 China
NR
60 158 104/54 I–IV  > 0 score (0–3) 60 OS R-Multi 6
Jiang
2016 [54]
Oct-4 China
2001–2010
62 (30–85) 412 284/128 I–IV  ≥ 4 score 60 OS R-Multi 7
Javanbakht 2017 [55] Oct-4 Iran
2010–2014
59.3 (37–85) 40 16/24 I–IV  > 25% 50 OS R-Multi 6
El-Guindy
2019 [56]
Oct-4 Egypt
2015–2016
18–70 45 28/17 I–III  ≥ 6 score (0–9) 24 OS, DFS E 6
Li
2014 [57]
ALDH1 China
2005–2008
57.0 ( 22–82) 216 140/76 I–III  ≥ 2 score (0–3) 27 (4–82) OS, RFS R-Multi 8
41Lu
2018 [58]
ALDH1 China
2011–2012
60 232 148/84 I–III  > 2 score (0–12) 48.7 (10–83) OS R-Multi 7
Simon
2012 [59]
LGR-5 Germany
1997–2009
68 + _11.4 487 304/183 I–IV NR 60.9 (14.3–129.9) OS E 6
Bu
2013 [60]
LGR-5 China
2002–2007
61 (22–87) 257 185/72 I–IV  ≥ 3 score (0–6) 60 OS R-Uni 8
Xi
2014 [61]
LGR-5 China
1999–2004
59.6 (24–86) 318 254/59 I–IV  ≥ 2 score (0–6) 120 OS R-Multi 7
Choi
2017 [62]
LGR-5 Korea
2004–2006
60 456 312/144 I–IV NR NR CSS R-Multi 6
Liu
2019 [63]
LGR-5 China
2009–2014
60 (33 to 85) 100 68/32 I–III  > 6 score (0–12) 60 OS E 8
Liu
2008 [64]
Bmi-1 China
1999–2002
60 146 92/54 I–IV  ≥ 10% 48 OS R-Multi 7
Zhang
2010 [65]
Bmi-1 China
NR
60 75 50/25 I–IV  ≥ 10% 110 OS E 7
Yang
2011 [66]
Bmi-1 China
2004–2005
60 219 162/57 I–IV  ≥ 20% 29.57 (1.90–78.10) DSS E 7
Wu
2016 [67]
Bmi-1 China
NR
60 352 236/116 I–IV NR 120 OS E 6
Lu
2012 [68]
Bmi-1 China
1993–2006
55 309 98/211 NR  > 5% 67.8 (2–200) OS E 7
Lin
2012 [69]
Nanog China
NR
50 105 71/34 I–IV  > 2 score (0–12) 60 OS R-Multi 7
Chou
2007 [70]
CD24 Taiwan
1995–1997
73 (40–99) 103 75/28 I–IV  > 10% 86.5 (1–120) OS R-Multi 6
Fujikuni
2014 [71]
CD24 Japan
2001–2008
65 119 73/46 I–III  > 1% 60 OS E 6
Darwish
2004 [72]
CD24 Korea
NR
54.3 300 200/100 I–IV NR 53 (1–72) OS R-Multi 8
Bektas
2010 [73]
CD24 Turkey
2001–2009
61.5 (30–84) 93 59/34 I–IV  > 10% 36 (0–100) OS E 8
Hu
2017 [74]
Gli-1, Shh China
NR
60 90 53/37 I–IV  ≥ 6 score (0–12) 80 OS E 6
Shao
2017 [75]
Gli-1 China
2008–2010
60 67 50/17 I–IV  ≥ 5 score (0–12) 60 OS R-Multi 9
Tang
2018 [76]
Gli-1 China
2009–2010
60 90 68/22 I–IV  > 3 score (0–9) 80 OS R-Multi 7
Ke
2020 [77]
Gli-1, Shh China
2010–2013
60 128 128/50 I–III  > 3 score 120 OS R-Multi 8
Wang
2014 [78]
Gli-1 China
2005–2007
63 (46–83) 121 92/29 I–IV  ≥ 10% 30 ( 5–60) OS R-Multi 7
Yao
2019 [79]
Gli-1 China
2010–2012
60 57 40/17 I–IV  ≥ 5 score (0–12) 60 OS E 9
Ertao
2016 [80]
Shh China
2004–2005
60 117 71/46 I–IV  > 10% 47.6 (3–114) OS R-Multi 8
Kim
2012 [81]
Shh Korea
2004–2007
NR 319 NR I–IV  > 3 score (0–4) 80 OS E 6
Yoo
2011 [82]
Shh Korea
2002–2004
60 178 124/49 I–IV NR 60 OS E 7
Niu
2014 [83]
Shh China
2008–2009
54.37 (22–75) 113 73/40 I–IV  ≥ 2 score (0–3) 43.6 (6–78) OS R-Multi 7
  1. HR: Hazard ratio; OS: Overall survival; RFS: Relapse-free survival; DSS: Disease-specific survival; DFS: Disease-free survival; CSS: Cancer-specific survival; NR: Not reported; IHC: Immunohistochemistry; E: Estimated by survival curve; R: Reported; R-Uni: Univariate analysis reported by article; R-Multi: Multivariate analysis reported by article; # Study quality was evaluated according to the Newcastle–Ottawa Scale (range, 1–9)